Epalinges
Switzerland
2
2013-12-19
2
2015-10-06
These are the the leading inventors for applications assigned to XIGEN S.A.:
XIGEN S.A. based in Epalinges, CH has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:
Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
#2 | 2013-07-04 ✅ Patent 8,981,052 granted on 2015-03-17JNK inhibitor molecules
29164 ⎘